exhibit 10. 3 agreement on termination of agreements between desitin arzneimittel gmbh and zogenix, inc. by and between zogenix, inc., whose registered office is at 12400 high bluff drive, suite 650, san diego, ca 92130, usa ( hereafter « zogenix » ) and desitin arzneimittel gmbh, whose registered office is at weg beim jager 214, 22335 hamburg, germany ( hereafter « desitin » ) each also referred to as “ party ” or together as “ parties ”. defined terms used in this agreement without definition shall have the meanings given them in the license agreement ( as defined below ). whereas - the parties have entered into a licensing and distribution agreement ( the “ license agreement ” ) signed on march 14, 2008 covering the development and commercialization of the product in the territory. - - the parties have entered into a licensing and distribution agreement ( the “ license agreement ” ) signed on march 14, 2008 covering the development and commercialization of the product in the territory. the parties have entered into a licensing and distribution agreement ( the “ license agreement ” ) signed on march 14, 2008 covering the development and commercialization of the product in the territory. - the parties have entered into a manufacturing agreement ( the “ manufacturing agreement ” ) signed on january 21, 2011 covering the manufacturing and supply of the product for commercialization in the territory. - - the parties have entered into a manufacturing agreement ( the “ manufacturing agreement ” ) signed on january 21, 2011 covering the manufacturing and supply of the product for commercialization in the territory. the parties have entered into a manufacturing agreement ( the “ manufacturing agreement ” ) signed on january 21, 2011 covering the manufacturing and supply of the product for commercialization in the territory. - desitin holds marketing authorisations for the product in germany, denmark, uk, france, norway and sweden. - - desitin holds marketing authorisations for the product in germany, denmark, uk, france, norway and sweden. desitin holds marketing authorisations for the product in germany, denmark, uk, france, norway and sweden. - desitin commercializes the product in germany and denmark ( as sumavel® dosepro® ). the product has never been launched in uk, france, norway and sweden. - - desitin commercializes the product in germany and denmark